Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported R&D Expense of $300.27 million for fiscal year 2025.
IOVANCE BIOTHERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $300.27M | +8.7% |
| 2024 | $276.23M | -17.1% |
| 2023 | $333.19M | +13.0% |
| 2022 | $294.78M | +13.8% |
| 2021 | $259.04M | +28.4% |
| 2020 | $201.73M | +21.5% |
| 2019 | $166.02M | +66.3% |
| 2018 | $99.83M | +39.4% |
| 2017 | $71.61M | +165.8% |
| 2016 | $26.94M | +74.1% |
| 2015 | $15.47M | +301.9% |
| 2014 | $3.85M | +78.7% |
| 2013 | $2.15M | +30.1% |
| 2012 | $1.66M | -5.7% |
| 2011 | $1.76M | +923.7% |
| 2010 | $171.5K | — |
| 2009 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $75.17M | +12.1% | -5.3% |
| June 30, 2025 | $79.36M | +27.8% | +3.2% |
| March 31, 2025 | $76.88M | -3.6% | +14.7% |
| September 30, 2024 | $67.04M | -23.4% | +8.0% |
| June 30, 2024 | $62.08M | -28.1% | -22.2% |
| March 31, 2024 | $79.78M | -3.6% | -8.8% |
| September 30, 2023 | $87.53M | +20.7% | +1.4% |
| June 30, 2023 | $86.35M | +17.6% | +4.4% |
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +8.7% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from IOVANCE BIOTHERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: